🔍

National Peroxide Ltd (544205)

📊 BSE: 544205 🏢 Commodity Chemicals 📢 Latest filing: 01 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, National Peroxide's revenue was ₹96.1 Cr (+44.1% year on year, +12.1% on the previous quarter), and net profit ₹6.6 Cr (+642.6% year on year); the operating margin was 12.7%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹96.1	+44.1%	+12.1%
Operating profit	₹12.2	+154.0%	-17.7%
Net profit	₹6.6	+642.6%	-16.7%
EPS (₹)	11.50	+641.9%	-16.7%
Operating margin	12.7%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

National Peroxide Appoints Vinay Jayade as CEO & Whole-Time Director for 5-Year Term

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 01 Oct 2026, 05:23 PM

National Peroxide has announced leadership changes following the resignation of Whole-Time Director & CEO Rajiv Arora due to family and personal reasons. Mr. Arora will step down on November 2, 2026, after an orderly transition period. The Board approved the appointment of Vinay Divakar Jayade as CEO and Whole-Time Director for a 5-year term starting November 3, 2026, subject to shareholder approval. Mr. Jayade brings over 34 years of specialty chemicals experience, including prior roles as JV President of Cabot Sanmar and MD of ASK Chemicals India.

Rajiv Arora resigns as Whole-Time Director & CEO, effective November 2, 2026
Vinay Divakar Jayade appointed as CEO and Whole-Time Director for a term of 5 years starting November 3, 2026
Mr. Jayade will serve as CEO & Whole-Time Director (Designate) during the transition starting October 1, 2026
Incoming CEO brings over 34 years of experience across specialty chemicals and polymer sectors

💡 Track the upcoming shareholder voting for the approval of the new CEO's appointment and monitor upcoming quarterly operational execution under the new leadership.

National Peroxide Appoints Vinay Jayade as CEO & Whole-Time Director for 5-Year Term

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 01 Oct 2026, 05:21 PM

Rajiv Arora resigns as Whole-Time Director & CEO, effective November 2, 2026
Vinay Divakar Jayade appointed as CEO and Whole-Time Director for a term of 5 years starting November 3, 2026
Mr. Jayade will serve as CEO & Whole-Time Director (Designate) during the transition starting October 1, 2026
Incoming CEO brings over 34 years of experience across specialty chemicals and polymer sectors

💡 Track the upcoming shareholder voting for the approval of the new CEO's appointment and monitor upcoming quarterly operational execution under the new leadership.

National Peroxide Appoints Vinay Jayade as CEO & Whole-Time Director for 5-Year Term

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 01 Oct 2026, 05:18 PM

Rajiv Arora resigns as Whole-Time Director & CEO, effective November 2, 2026
Vinay Divakar Jayade appointed as CEO and Whole-Time Director for a term of 5 years starting November 3, 2026
Mr. Jayade will serve as CEO & Whole-Time Director (Designate) during the transition starting October 1, 2026
Incoming CEO brings over 34 years of experience across specialty chemicals and polymer sectors

💡 Track the upcoming shareholder voting for the approval of the new CEO's appointment and monitor upcoming quarterly operational execution under the new leadership.

National Peroxide Holds 6th AGM; Considers ₹7.00 Per Share Final Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Sep 2026, 08:19 PM

National Peroxide Limited concluded its 6th Annual General Meeting on September 29, 2026. Key business transacted included the adoption of FY26 financial statements and approval of a ₹7.00 per share final dividend (70% on face value of ₹10). Other resolutions included the reappointment of Mr. Ness N. Wadia as Director and Kalyaniwalla & Mistry LLP as statutory auditors. Final voting results will be announced on or before October 1, 2026.

AGM held virtually on September 29, 2026, from 11:00 AM to 12:00 noon IST
Considered a final dividend of ₹7.00 per share (70% on face value of ₹10) for FY26
5 ordinary resolutions tabled, including the reappointment of Director Ness N. Wadia
E-voting scrutiny results to be announced on or before October 1, 2026

💡 Track the formal declaration of scrutinizer voting results by October 1, 2026, and the subsequent dividend payment timeline.

₹7 Dividend Confirmed; FY26 Profits Restated Downward Due to ERP Accounting Error

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 12 Aug 2026, 01:31 PM

National Peroxide has confirmed a final dividend of ₹7 per share (1.2% yield) for FY26, with the record date set for September 22, 2026. However, the company revealed a significant restatement of its FY26 financial results due to an ERP error that understated natural gas costs, leading to a downward revision of previously reported profits. For Q1 FY27 (June 2026), the company reported revenue of ₹76.40 cr and a net profit of only ₹0.89 cr, a sharp decline from the restated March 2026 quarter profit of ₹5.82 cr. Investors should note the high dividend payout ratio of approximately 43% of restated FY26 PAT despite the internal control lapse and declining quarterly margins.

Final dividend of ₹7 per equity share (70% of face value) recommended for FY26.
FY26 net profit restated to ₹9.23 cr following discovery of incorrect ERP configuration for natural gas invoices.
Q1 FY27 (June 2026) net profit fell sharply to ₹0.89 cr compared to ₹5.82 cr in the preceding quarter.
Record date for dividend entitlement and AGM participation set for September 22, 2026.
Statutory auditors Kalyaniwalla & Mistry LLP re-appointed for a second 5-year term through FY2031.

💡 Monitor the upcoming AGM on September 29, 2026, for management commentary on internal control remediations and the sharp compression in Q1 FY27 operating margins.

National Peroxide Restates FY26 Profits Due to ERP Error; Confirms ₹7 Dividend

🔵 WATCH ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:27 PM

National Peroxide has restated its FY26 and Q3 FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs, leading to a prior overstatement of profits. Despite this correction, the Board maintained its previously recommended final dividend of ₹7 per share (70% of face value). For Q1 FY27 (June 2026), the company reported a revenue of ₹76.40 Cr and a net profit of ₹0.89 Cr, with an EPS of ₹1.55. The record date for the dividend and the 6th Annual General Meeting is set for September 22, 2026.

Restatement of FY26 results due to incorrect ERP configuration for natural gas invoices, which understated raw material costs.
Final dividend of ₹7 per share confirmed for FY26, representing a 70% payout on the ₹10 face value.
Q1 FY27 revenue reported at ₹76.40 Cr, approximately 26% of the TTM revenue of ₹290 Cr.
Q1 FY27 net profit stood at ₹0.89 Cr with an EPS of ₹1.55, matching the previous year's June quarter performance.
Record date for dividend entitlement and AGM participation fixed as September 22, 2026.

💡 Investors should monitor the revised FY26 audit report for the exact magnitude of the profit overstatement and watch for improvements in internal financial controls to prevent future ERP-related accounting errors.

National Peroxide Restates FY26 Profits Due to ERP Error; Maintains Rs 7 Dividend

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 12 Aug 2026, 01:23 PM

National Peroxide has restated its FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs and overstated profits. Despite this correction, the Board has maintained its recommended final dividend of Rs 7 per share (70% of face value). For the first quarter of FY27 (ended June 30, 2026), the company reported a Profit After Tax of Rs 5.82 crore. The 6th Annual General Meeting is scheduled for September 29, 2026, with a record date of September 22, 2026.

Restatement of FY26 and Q3 FY26 results due to incorrect natural gas invoice processing in the ERP system
Recommended final dividend of Rs 7 per share (70%) for FY26 remains unchanged
Reported Q1 FY27 (June 2026) Profit After Tax of Rs 5.82 crore
Record date for dividend and AGM entitlement set for September 22, 2026
Statutory auditors Kalyaniwalla & Mistry LLP reappointed for a second 5-year term until FY31

💡 Monitor the company's upcoming annual report for details on internal control improvements to prevent further ERP-related accounting errors.

National Peroxide Restates FY26 Profit Downward to ₹9.23 Cr; Maintains ₹7 Dividend

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 12 Aug 2026, 01:21 PM

National Peroxide has restated its FY26 and Q3 FY26 financial results due to an ERP configuration error that understated natural gas raw material costs. The revised FY26 Profit After Tax (PAT) is now ₹9.23 Cr, a downward revision from previously reported figures. Despite the accounting error, the Board maintained its recommended final dividend of ₹7 per share (70% of face value). For Q1 FY27 (ended June 2026), the company reported a PAT of ₹5.82 Cr, showing a recovery compared to the restated Q4 FY26 PAT of ₹0.89 Cr.

Restatement of FY26 results due to incorrect ERP configuration for natural gas invoices, leading to previously overstated profits.
Revised FY26 Profit After Tax stands at ₹9.23 Cr, while Q1 FY27 PAT is reported at ₹5.82 Cr.
Final dividend of ₹7 per share recommended, representing a ~1.2% yield on the current price of ₹575.2.
Record date for the dividend and 6th Annual General Meeting set for September 22, 2026.
Reappointment of M/s. Kalyaniwalla & Mistry LLP as Statutory Auditors for a second 5-year term until FY31.

💡 Investors should monitor management's commentary during the AGM on September 29, 2026, regarding the strengthening of internal financial controls and ERP systems to prevent future restatements.

Q1 Profit Rises to ₹5.82 Cr; FY26 Results Restated Downward due to ERP Accounting Error

🔵 WATCH ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:18 PM

National Peroxide reported a significant recovery in Q1 FY27, with net profit jumping to ₹5.82 Cr from ₹0.89 Cr in the year-ago period. Revenue grew 13.5% YoY to ₹76.40 Cr. However, the company has retrospectively restated its FY26 results downward after discovering an ERP configuration error that understated natural gas costs. The revised FY26 PAT is now ₹9.23 Cr, down from the previously reported ~₹11 Cr. The board confirmed a final dividend of ₹7 per share with a record date of September 22, 2026.

Q1 FY27 net profit increased to ₹5.82 Cr, a 554% jump from ₹0.89 Cr in Q1 FY26.
Revenue for the June 2026 quarter rose to ₹76.40 Cr compared to ₹67.32 Cr in the previous year's corresponding quarter.
FY26 financial results restated due to incorrect ERP configuration for natural gas invoices, which previously overstated profits.
Final dividend of ₹7 per share (70%) confirmed for FY26, representing a yield of ~1.2% at current prices.
Statutory auditors Kalyaniwalla & Mistry LLP reappointed for a second 5-year term until FY2031.

💡 Investors should monitor the sustainability of the improved Q1 margins and verify if the internal control weaknesses related to the ERP system have been fully remediated.

National Peroxide Revises FY26 PAT Downward to ₹9.23 Cr Due to ERP Accounting Error

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 01:16 PM

National Peroxide has restated its FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs. The revised FY26 Profit After Tax (PAT) stands at ₹9.23 Cr, a reduction from the previously reported figures. For Q1 FY27, the company reported a PAT of ₹5.82 Cr on revenue of ₹84.47 Cr, showing a strong start to the new fiscal year. The board maintained its recommended final dividend of ₹7 per share (70%) despite the restatement.

Revised FY26 PAT stands at ₹9.23 Cr following a retrospective restatement due to ERP invoice processing errors.
Q1 FY27 PAT reported at ₹5.82 Cr, which is approximately 63% of the total revised PAT for the entire previous year.
Q1 FY27 Revenue from operations reached ₹84.47 Cr, representing ~29% of TTM revenue.
Final dividend of ₹7 per share (70%) confirmed with a Record Date of September 22, 2026.
Statutory auditors re-appointed for a second 5-year term until FY31, subject to AGM approval.

💡 Investors should monitor the company's internal financial control disclosures in the upcoming Annual Report to ensure the ERP configuration issues are fully resolved. The strong Q1 FY27 performance provides some cushion against the negative sentiment of the restatement.

National Peroxide revises FY26 PAT to ₹9.23 Cr; reports Q1 FY27 PAT of ₹6.61 Cr

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 12 Aug 2026, 01:09 PM

National Peroxide has restated its FY26 and Q3 FY26 financial results due to an ERP configuration error that understated natural gas costs, leading to a prior overstatement of profits. The revised FY26 PAT now stands at ₹9.23 Cr. For the current quarter (Q1 FY27), the company reported a PAT of ₹6.61 Cr on a total income of ₹84.47 Cr. The board maintained its ₹7 per share dividend recommendation and reappointed its statutory auditors for a five-year term.

Revised FY26 PAT to ₹9.23 Cr from previously reported figures due to natural gas invoice processing errors in the ERP system
Reported Q1 FY27 PAT of ₹6.61 Cr, showing significant recovery compared to the revised Q4 FY26 PAT of ₹0.89 Cr
Maintained final dividend of ₹7 per equity share (70%) for FY26, with a record date set for September 22, 2026
Reappointed M/s. Kalyaniwalla & Mistry LLP as Statutory Auditors for a second 5-year term until FY31
Total income for Q1 FY27 stood at ₹84.47 Cr with an EPS of ₹11.50 for the quarter

💡 Investors should monitor the company's disclosure regarding internal financial control improvements to address the ERP configuration issues. The operational recovery in Q1 FY27 is positive, but the sensitivity to natural gas pricing remains a key variable for this single-segment business.

National Peroxide Restates FY26 Profits Due to ERP Error; Maintains ₹7 Dividend

🔴 NEGATIVE ⭐ 7/10

BOARD_MEETING 📅 12 Aug 2026, 01:08 PM

National Peroxide has retrospectively restated its FY26 and Q3 FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs, leading to a prior overstatement of profits. For the new quarter ended June 30, 2026, the company reported a net profit of ₹0.89 Cr on revenue of ₹84.47 Cr. Despite the accounting correction, the board maintained its recommended final dividend of ₹7 per share (70%). The statutory auditor has been reappointed for a second 5-year term, though the revised audit report includes an 'Emphasis of Matter' regarding the restatement.

Restatement of FY26 and Q3 FY26 results due to incorrect ERP configuration for natural gas invoices.
Maintained final dividend of ₹7 per equity share (70%) for the financial year ended March 31, 2026.
Reported Q1 FY27 net profit of ₹0.89 Cr, a significant drop from the restated Q4 FY26 profit of ₹5.82 Cr.
Record date for the final dividend and 6th Annual General Meeting set for September 22, 2026.
Statutory auditors Kalyaniwalla & Mistry LLP reappointed for a 5-year term until the 11th AGM in 2031.

💡 Investors should monitor the upcoming Annual Report for details on how internal financial controls are being strengthened to prevent future ERP-related accounting errors.

Board Meeting on Aug 12 to approve Q1 results and Revised FY26 Audited Financial s

🔵 WATCH ⭐ 4/10

BOARD_MEETING 📅 09 Aug 2026, 05:46 PM

National Peroxide has scheduled a board meeting for August 12, 2026, to approve un-audited financial results for the quarter ended June 30, 2026. Critically, the board will also consider and approve 'Revised Audited Financial Results' for the financial year ended March 31, 2026. This revision follows a period where the company reported a TTM revenue of Rs 290 Cr and a PAT of Rs 11 Cr. The need for revised audited statements is unusual and will be closely watched by the market.

Board meeting scheduled for August 12, 2026, to review both quarterly and annual performance.
Includes approval of Revised Audited Financial Results for the full year ended March 31, 2026.
Schedule includes Un-audited Financial Results for the firs t quarter ended June 30, 2026.
Company currently has a market cap of Rs 328 Cr with a TTM PAT of Rs 11 Cr.

💡 Investors should scrutinize the nature of the 'revision' to the FY26 audited figures on August 12 to understand if they stem for m accounting reclassification s or material error s.

National Peroxide Defers August 03 Board Meeting for Q1 FY27 Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 02 Aug 2026, 03:28 PM

National Peroxide Ltd has deferred its Board Meeting originally scheduled for August 03, 2026, which was set to approve the unaudited financial results for the quarter ended June 30, 2026. The company cited 'unavoidable circumstances' for the postponement and stated that a revised date will be communicated in due course. The trading window for designated persons remains closed since July 01, 2026, and will continue until 48 hours after the eventual results declaration. This delay is administrative but postpones the market's ability to assess the company's performance following a profitable FY26 (PAT of Rs 11 Cr).

Board meeting scheduled for August 03, 2026, has been cancelled/deferred.
The meeting was intended to approve unaudited financial results for the quarter ended June 30, 2026.
Trading window for securities has been closed since July 01, 2026, and will remain closed until 48 hours post-results.
Company reported a TTM revenue of Rs 290 Cr and a TTM PAT of Rs 11 Cr as of the latest available data.

💡 Investors should monitor the exchange filings for the announcement of the revised board meeting date to evaluate the company's Q1 FY27 performance.

National Peroxide Board Meeting on Aug 3, 2026 to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 29 Jul 2026, 05:15 PM

National Peroxide Ltd has scheduled a board meeting on August 3, 2026, to review and approve unaudited financial results for the quarter ended June 30, 2026. The company is coming off a strong FY26 where it turned profitable with a PAT of ₹11 cr compared to a loss of ₹2 cr in FY25. Trailing twelve-month (TTM) revenue stands at ₹290 cr, with the March 2026 quarter showing peak quarterly revenue of ₹85.68 cr. Investors will be looking for consistency in operating margins, which averaged 10.8% over the last four quarters.